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Nonreducible cystine isosteres represent important peptide design elements in that they can maintain a near-native tertiary
conformation of the peptide while simultaneously extending the in vitro and in vivo half-life of the biomolecule. Examples of these
cystine mimics include dicarba, diselenide, thioether, triazole, and lactam bridges. Each has unique physicochemical properties
that impact upon the resulting peptide conformation. Each also requires specific conditions for its formation via chemical peptide
synthesis protocols. While the preparation of peptides containing two lactam bonds within a peptide is technically possible and
reported by others, to date there has been no report of the chemical synthesis of a heterodimeric peptide linked by two lactambonds.
To examine the feasibility of such an assembly, judicious use of a complementary combination of amine and acid protecting groups
together with nonfragment-based, total stepwise solid phase peptide synthesis led to the successful preparation of an analogue of
themodel peptide, insulin-like peptide 3 (INSL3), in which both of the interchain disulfide bonds were replacedwith a lactam bond.
An analogue containing a single disulfide-substituted interchain lactam bond was also prepared. Both INSL3 analogues retained
significant cognate RXFP2 receptor binding affinity.
1. Introduction
Cysteine-rich peptides such as conotoxins and insulin-like
peptides are an increasingly important class of biomolecules.
They usually possess intricately folded, sometimes knotted,
structures and some have been developed as treatments
for a variety of conditions, such as pain [1, 2], cancer [3],
diabetes mellitus [4], and heart failure [5, 6]. As such, much
work is being undertaken to optimise their pharmacological
properties so that new lead compounds are developed for
preclinical evaluation. Disulfide bonds play a critical role in
maintaining the peptide conformation and biological activity
of thesemolecules.However, they are susceptible to reduction
in vivo, as part of the normal degradative process which, in
turn, can disrupt the three-dimensional structure and lead to
loss of activity. In order to stabilise peptide structures, numer-
ous disulfide bond mimics have been developed. Guo et al.
substituted a diselenide for a disulfide bond in a sunflower
trypsin inhibitor which retained high potency [7]. Armishaw
et al. also applied this further to an 𝛼-conotoxin, which
maintained full biological activity and had enhanced stability
under biologically reducing conditions [8]. This same model
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peptide was also prepared with thioether bonds as cystine
mimics, and a similar outcome was achieved with respect to
both activity and stability [9]. Further, Holland-Nell andMel-
dal reported that 1,4-triazoles using the copper(I)-catalysed
azide-alkyne cycloaddition can also be a useful cystine
isostere [10]. Further work in this area has demonstrated that
1,5-triazoles, produced via ruthenium(II) catalysis, can be an
even more effective mimic [11]. Numerous dicarba analogues
of cystine-containing peptides have also been prepared [12–
15] and shown to possess near-native structure and extended
in vivo stability. Monosubstituted dicarba bond analogues
of the heterodimeric peptides relaxin-3 [16] and insulin-like
peptide 3 (INSL3) [17] have also been prepared and evaluated.
The incorporation of lactam bridges in peptides has been
widely reported in the literature. Such linkages have been
employed as both “staples” in order to stabilise 𝛼-helices
and other secondary structures [18–20] and as a strategy for
generating small cyclic libraries [21]. They have also found
use of stable cystine isosteres [21–28] as an alternative to
the previous methods described. These linkages have two
key structural characteristics: (i) there are dual orientations
of the asymmetrical amide bond; (ii) bridge length can
vary. The direction of the lactam bond can have either a
negligible effect on binding and biological activity [22] or a
dramatic one. Interestingly, Hargittai and coworkers found
that an 𝛼-conotoxin analogue with a Lys/Glu lactam bond
was 4,000 times more potent than the “inverted” Glu/Lys
analogue [23]. Different pairings of side-chain carboxylate
(Asp, Glu) and amine (Dpr, Dab, Orn, Lys) residues will of
course vary the length of the lactam bridge which can also
affect peptide conformation and activity [24–26]. The most
common residue used is an aspartyl/2,3-diaminopropionyl
pairing, since the resultant side-chain to side-chain amide
bond will result in the same number of atoms as a cystine
bond.
There have been a number of methods developed for
synthesising lactam-containing peptides [22, 26–28]. Earlier
work focussed on a Boc/Bzl-based strategy, employing the
base-labile O-Fm and Fmoc protecting groups for orthogonal
protection of carboxylate and amine side-chains, respectively.
Typically, the lactam is formed on the solid support, followed
by HF cleavage and RP-HPLC. This methodology has been
extended to assemble bis-lactam analogues [18] including
peptides with overlapping lactam bonds [19]. The latter
was performed by employing hydrazine labile O-Dmab and
Dde protecting groups in addition to the 9-fluorenylmethyl-
based ones as semiorthogonal protection. Thurieau et al.
devised a solution-phase approach whereby the N-terminus
and a lysine residue were protected until after lactamization
in order to yield one discrete product [24]. Allyl/Alloc
protection is a common strategy when using an “on-resin”
Fmoc/tBu approach [21, 23, 24, 28] as it is the extremely acid-
labile and more convenient O-2-PhiPr/Mtt pair [20, 29].
INSL3 was chosen as themodel system to evaluate lactam
bonds as cystine isosteres in complex peptide structures.
INSL3 is a hormone which has been shown to play an impor-
tant role in testicular descent during sexual development [30].
It is heterodimeric in nature with a 26 residue A-chain and a
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Figure 1: Primary structure of (a) human INSL3 and (b) its analogue
ΔA25/26 human INSL3.
31 residue B-chain. It contains a disulfide bonding configura-
tion, that is, characteristic of the insulin/relaxin superfamily
[31] with one intra-A-chain and two interchain (between A
and B) cystine bonds which stabilize the three-dimensional
structure of the peptide (Figure 1(a)). Its structure-activity
relationship has been studied in detail, and both the A- and
B-chains are required for RXFP2 receptor activation [32–34].
Further, an analogue of the INSL3 B-chain alone was shown
to be a potent RXFP2 antagonist [35]. Recently, Bu¨llesbach
and Schwabe prepared analogues of human INSL3 in which
one or the other of the two interchain disulfide bonds were
replaced with a lactam bond, in which the purpose was
to study the role of the native cystine (A11-B10) and (A24-
B22) bonds in both binding and receptor activation [29].
Their synthetic strategy involved native chemical ligation
of two A-chain fragments followed by a second ligation
with the B-chain. While very effective, the methodology
requires the preparation of peptide thioesters as ligation
intermediates prior to subsequent off-resin preparation of the
mono-intrachain lactam INSL3 analogue.
Moreover, to date, there have been no reports of a
chemical synthesis of a bis-lactam cross-linked heterodimeric
peptide. Consequently, in this study, we undertook an exam-
ination of the feasibility of a total step-wise synthesis of,
first, a monolactam A24-B22 analogue and, subsequently, a
bis-lactam A11-B10/A24-B22 analogue of INSL3. Our novel
strategy involved the continuous assembly of both the A-
and B-chains, plus the lactam bridges on the same solid
support, that is, without using preformed peptide fragments.
In order to simplify assembly, the C-terminus of the A-chain
was truncated at position 24, omitting ProA25 and TyrA26 that
results in the analogue ΔA25/26 human INSL3 (Figure 1(b)).
Although receptor activation is somewhat diminished for this
particular analogue, it still demonstrates significant binding
affinity compared to that of the native form [32] and hence
was deemed to be a suitable model system to evaluate the
synthetic feasibility of assembling these lactam analogues.
We describe herein the synthesis of ΔA25/26 human INSL3
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having a lactam substitution of CysA24,B10 as well as a first
ever reported assembly of a heterodimeric analogue with two
interchain lactam bridges, namely, ΔA25/26 human INSL3
bis-lactam A11-B10/A24-B22. The cognate RXFP2 G protein-
coupled receptor binding affinity of the analogues was also
evaluated.
2. Materials and Methods
2.1. Solid Phase Peptide Synthesis. All peptides were assem-
bled on a CEM Liberty microwave peptide synthesiser
(DKSH, Australia), except for when an unusual amino
acid derivative was used whereby it was coupled manually.
Standard Fmoc amino acids were obtained from GL Bio-
chem (China) as was HATU and Boc anhydride. Fmoc-L-
Asp-OtBu, Fmoc-L-Dpr(ivDde)-OH, Fmoc-L-Dpr(Mmt)-
OH, and Fmoc-L-Asp(O-2-PhiPr)-OH were sourced from
Novabiochem (Australia). Piperidine, hydrazine, DIPEA,
NMP, TIPS, DODT, TFA, iodine, and DOWEX ion exchange
resin were obtained from Sigma-Aldrich (Australia). DCM
and DMF were purchased from Ajax Finechem P/L (Aus-
tralia). Fmoc-L-Ala-PEG-PS resin with a substitution of
0.2mmol/g was obtained from Applied Biosystems (Aus-
tralia).
2.2. RP-HPLC Purification and Analysis. All peptides were
analysed on an Agilent 1100 Series HPLC (Australia) with
an Agilent Eclipse XDB-C18 column (5 𝜇m, 4.6 × 150mm).
The buffer system used was 0.1% TFA in water (buffer A)
and 0.1% TFA in acetonitrile (buffer B). A typical gradient
was 0–80% buffer B over 40 minutes at a 1mL/min flow
rate with the detection at 220 nm. Purification was carried
out on an Agilent 1200 Series HPLC using either an Agilent
Eclipse XDB-C18 column (5 𝜇m, 9.4mm × 250mm) or
a Phenomenex Synergi Hydro C18 column (4𝜇m, 21.2 ×
50mm).A typical gradient of 0–60%buffer B over 60minutes
at a flow rate of 5mL/min was used.
2.3. Mass Spectrometry. The linear and intermediate peptides
were characterised on an Agilent 6510 Dual ESI QTOF mass
spectrometer (Australia).
2.4. Receptor Binding Assay. The receptor binding affinity of
both analogues was determined in HEK-293T cells stably
transfected with RXFP2 as previously described [32]. Briefly,
a single concentration of europium-labelled INSL3 (0.3 nM)
[36] was used in the presence of increasing concentration
of the unlabelled INSL3 and the analogues (0.01 nM–1 𝜇M).
The data was analysed using GraphPad PRISM 4 (GraphPad
Inc., San Diego, USA) and expressed as mean ± SEM of
three independent experiments. The statistical differences in
pK
𝑖
values were calculated using one-way ANOVA coupled
to Bonferroni’s multiple comparison test for multiple group
comparisons.
2.5. Synthesis of ΔA25/26 Human INSL3 Monolactam A24-
B22. INSL3 B-chain was assembled on Fmoc-L-Ala-PEG-
PS resin via microwave-assisted SPPS on a 50 𝜇mol scale
using an Fmoc SPPS approach. ivDde-protected diaminopro-
pionic acid (Dpr) was used in place of CysB22, and CysB10
was incorporated with acetamidomethyl (Acm) protection.
After chain elongation, the N-terminus of the resin-bound
peptide was Boc-protected using di-tert-butyl carbonate in
the presence of DIPEA, followed by treatment with a solution
of 3% hydrazine (5 × 3 minutes) to cleave the ivDde group.
The free amine at the side-chain was then acylated via
the HATU activated side-chain of Fmoc-L-Asp-OtBu, and
the A-chain was then assembled on the same resin. CysA11
was also incorporated with Acm protection. The peptide
was then TFA-cleaved, isolated, and then RP-HPLC-purified.
The free sulfhydryls at residues CysA10 and CysA15 were
then oxidised with 2 equivalents of iodine in a 50% acetic
acid aqueous solution at a concentration of 1mg/mL for
30 minutes. Excess iodine was quenched with DOWEX ion
exchange resin, followed by a second RP-HPLC purification.
The CysA11-CysB10 intermolecular disulfide bond was then
formed via oxidative cleavage of both Cys(Acm) residues
using 20 equivalents of iodine [37]. After a similar workup
to the previous oxidation, the crude product was RP-HPLC-
purified to a high level and characterised via ESI-MS which
gave a molecular mass of 6011 Da (theory: 6011.0). The final
mass recoverywas 700𝜇g (yield 1.8% relative to starting crude
cleaved peptide).
2.6. Synthesis of ΔA25/26 Human INSL3 Bis-Lactam A11-
B10/A24-B22. A similar synthetic strategy was employed for
this synthesis on the same 50 𝜇mol scale; however, the lactam
bridge mimicking the CysA11-CysB10 bond was also formed
on the solid support. Thus B-chain was assembled using
Dpr(Mmt) and Dpr(ivDde) at positions B10 and B22, respec-
tively. His(Boc) was used instead of His(Trt) at positions
B12 and B13 and was incorporated manually under ambient
conditions using HOBt/DIC activation. After N-terminal
capping and ivDde cleavage, the A-chain was assembled
up to position A11 using an Asp(O-2-PhiPr) residue and
leaving the N-terminus Fmoc protected. At positions A17
and A18, unprotected Gln was incorporated (via HOBt/DIC
activation) instead of the usual Trt side-chain protected
derivative. The resin was then treated with 1% TFA (10 ×
3 minutes) to cleave the O-2-PhiPr and Mmt protecting
groups from the Asp and Dpr side-chains, respectively. After
neutralisation with mild base, the resin was treated with 1.5
equivalents of HATU in the presence of DIPEA to form the
A11-B10 interchain mimic. A small-scale pilot cleavage was
performed in order to determine the success of this on-resin
cyclisation. After reaction, the remainder of the A-chain was
assembled and the peptide was isolated and purified via RP-
HPLC. Oxidation of the CysA10-CysA15 pair was performed
using 2 equivalents of elemental iodine as described above.
The product was repurified and lyophilised. 20𝜇g of material
at high purity was recovered (0.08% relative to the isolated
crude material), and the peptide was characterised via ESI-
MS which showed a molecular mass of 5990Da (theory:
5989.8).
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Figure 2: Schematic representation of the synthesis of ΔA25/26
human INSL3 monolactam A24-B22. X = 2,3-diaminopropyl.
3. Results and Discussion
An initial assembly of the ΔA25/26 human INSL3 monolac-
tam A24-B22 was undertaken via total chemical synthesis
(Figure 2). This analogue was chosen over the ΔA25/26
human INSL3 monolactam A11-B10 analogue solely for
reasons of synthetic simplicity with the former having its
lactam bond closest to the C-terminus of the synthesis and
being theoretically easier to form first before steric crowding
became too great a consideration. The microwave-assisted
assembly was successful as indicated by RP-HPLC and ESI-
MS analysis of the crude S-reduced peptide (Figure 3(a)).
The principal impurities were identified to be postcleavage
tert-butyl adducts which are characteristic of thiol and
thioether-containing peptides. After RP-HPLC purification,
mild oxidative conditions were employed to form the first A-
chain intramolecular (A10-A15) disulfide bond, followed by a
second purification. The final oxidation step to form the A11-
B10 disulfide bond gave a number of side products which is a
common outcome from treating peptides with a large excess
of iodine [37]. Trp, Tyr, and Met residues can be modified,
all of which are present in INSL3. Furthermore, misfolded
isomers and dimers can occur due to disulfide shuffling.
Because of this complex mixture, a two-step purification was
performed, firstly using a conventional C18 Agilent column,
followed by a second C18 Phenomenex column with polar
residues bonded to the stationary phase.The rationale behind
this strategy was to achieve an alternative selectivity from
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Figure 3: RP-HPLC and ESI-MS data of ΔA25/26 human INSL3
monolactam A24-B22. (a) RP-HPLC of crude ΔA25/26 human
INSL3 A24-B22 CysA11,B10 di-Acm species; (b) RP-HPLC of purified
ΔA25/26 human INSL3 monolactam A24-B22; (c) ESI-MS of puri-
fiedΔA25/26 human INSL3monolactamA24-B22. HPLC detection
wavelength = 220 nm.
the chromatography such that most impurities coeluting
with the parent compound during the first isolation will be
separable during the second pass through the column. This
strategy yielded sufficient peptide to be obtained in high
purity (Figures 3(b) and 3(c)) which enabled the analogue to
be evaluated in the RXFP2 receptor-binding assay.
Assembly of the ΔA25/26 human INSL3 bis-lactam A11-
B10/A24-B22 analogue B-chain (Figure 4) also proceeded
smoothly as verified by a small-scale cleavage of the peptide
resin. After ivDde deprotection at DprB22, the A-chain was
assembled up to Fmoc-AspA11. RP-HPLC analysis indicated
that the target intermediate was the major product. It was
thought that forming the intermolecular lactam bond at this
point was preferable, since extending the A-chain beforehand
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Figure 4: Schematic representation of the synthesis of ΔA25/26
human INSL3 bis-lactamA11-B10/A24-B22. X = 2,3-diaminopropyl.
would increase the steric crowding on the resin, making
it difficult to drive the lactamization to completion. Using
the same rationale, Boc-protected HisB11 and HisB12 and
unprotected GlnA17 and GlnA18 were also used, instead of
the bulkier trityl-based derivatives. Deprotection of AspA11
and DprB10 with dilute TFA was monitored colorimetrically
via Trt cleavage; however, it was not possible to determine
whether full removal of the O-2-PhiPr moiety occurred. A
trial TFA deprotection showed that this protecting group
would cleave off regardless. After neutralisation of the resin,
the amide bond between residues A11 and B10 was formed.
RP-HPLC analysis found that there were a large number of
side products generated (Figure 5(a)), some of which were
likely to be oligomeric species caused by undesired cross-
linking within the solid support. Nevertheless, the last ten
residues were coupled under microwave-assisted conditions,
followed by cleavage and deprotection. As expected, the
crude material consisted of multiple products and a two-step
purification was again employed as described above in order
to isolate the semipure reduced species. Treatment with two
equivalents of iodine gave the desired product, and a second
two-step purificationwas performed, due to the complexity of
the mixture. Despite the low yield, sufficient purified peptide
was isolated (Figures 5(b) and 5(c)) for evaluation in the
binding assay.
Both the ΔA25/26 human INSL3 monolactam A24-B22
and bis-lactam A11-B10/A24-B22 analogues were tested in
the RXFP2 competition binding assay (Table 1). The receptor
binding affinity of each was found to be 8.35 ± 0.11 and 7.92
(m
AU
)
(min)
15 25
600
(a)
10 20
(m
AU
)
400
(min)
(b)
Io
n 
co
un
t
m/z
1200 14001000800
[M + 6H+]6+
[M + 8H+]8+
[M + 7H+]7+
[M + 4H+]4+
[M + 5H+]5+
(c)
Figure 5: RP-HPLC and ESI-MS data of ΔA25/26 human
INSL3 bis-lactam A11-B10/A24-B22. (a) RP-HPLC of crude Fmoc-
AspA10ΔA25/26 INSL3 A11-B10/A24-B22; (b) RP-HPLC of purified
ΔA25/26 human INSL3 bis-lactam A11-B10/A24-B22; (c) ESI-MS
of purified ΔA25/26 human INSL3 bis-lactam A11-B10/A24-B22.
HPLC detection wavelength = 220 nm.
± 0.12, respectively. While these values were approximately
10-fold and 12-fold lower compared to native INSL3 (9.24 ±
0.02), the more relevant comparison is with ΔA25,26 human
INSL3 (8.59 ± 0.06) which shows that both analogues are
only 1.7-fold and 4.6-fold lower. This showed that employing
lactam bridges as stable cystine isosteres in insulin-like
peptides holds much promise. The very modest reduction
in binding affinity of ΔA25/26 human INSL3 monolactam
A24-B22 compared to ΔA25/26 human INSL3 is consistent
with similar observations recently made for synthetic human
INSL3 monolactam A24-B22 versus native INSL3 [29]. The
reason for this is probably due to a subtle change in the
conformation that is caused by one or more of the following:
the shorter length of the amide bond compared to the
disulfide bond, change in the electronic nature of the cystine
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Table 1: Receptor binding affinities (pK
𝑖
) of INSL3 and analogues.
Data for entry 2 taken from reference [32].
Peptide Receptor binding pK𝑖(n=)
Human INSL3 9.24 ± 0.02 (6)
ΔA25/26 human INSL3 8.59 ± 0.06 (3)
ΔA25/26 human INSL3
mono-lactam A24-B22 8.35 ± 0.11 (3)
ΔA25/26 human INSL3
bis-lactam A11-B10, A24-B22 7.92 ± 0.12 (3)
mimic, and steric effects. Unfortunately, insufficient material
was obtained to perform structural studies using CD orNMR
spectroscopy [38, 39]. It was also not possible to perform
cAMP activity-based assays or, equally important, plasma
stability assays in order to verify whether the more stable
amide bond(s) gives the model peptides enhanced stability.
Yet importantly, this study demonstrates the feasibility of
acquiring such heterodimeric analogues although further
work is clearly required to improve their total synthesis
and subsequent yields of these analogues. This will include
employing different protecting group combinations (e.g.,
Allyl/Alloc), incorporating a solution-phase step, or using
a very low loading resin to minimize both steric crowding
during assembly and the nonspecificity of the on-resin
directed lactam bond formation [40].
In conclusion, a novel “two-chain assembly” strategy on
a solid support was developed for synthesising complex bis-
lactam interchain-linked heterodimeric insulin-like peptides
for the first time. This was achieved by use of microwave-
assisted SPPS and use of semiorthogonal side-chain protect-
ing groups. This approach enabled the preparation of both
mono- and bis-lactam analogues of ΔA25/26 human INSL3
which were subsequently shown to have significant binding
affinity at nanomolar concentration for RXFP2 receptor.
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